Revolutionizing Gene Therapy Manufacturing: Robotics And Machine Learning For Process Intensification

Despite significant progress in gene therapy, the industry continues to face persistent challenges, including prolonged development timelines and high manufacturing costs—particularly in viral vector production. To help overcome these barriers, we have developed an integrated production ecosystem that combines machine learning, high-throughput process and analytical development, and perfusion-based intensification strategies. This comprehensive approach has been successfully scaled from bench to 2,000 L, demonstrating its robustness and suitability for meeting the growing clinical demand for gene therapies.

In the webinar below, experts from Thermo Fisher Scientific highlight how this strategy enhances both the productivity and quality of viral vectors, featuring a high-throughput platform capable of screening up to 100 bioreactor conditions per week — including downstream purification and analytics — while leveraging machine learning and mechanistic modeling to predict upstream performance accurately. By integrating perfusion into upstream manufacturing, this approach has achieved up to a fivefold increase in productivity, delivering titers that significantly exceed current industry benchmarks.